Yellow Fever vaccination campaign in Togo

Vaccines are intended to save lives, but in rare cases, serious adverse events may occur. That’s why ongoing vaccine safety monitoring—or pharmacovigilance—is critical to ensure patient health and well-being.

The Role of Vaccine Pharmacovigilance

Among other things, vaccine pharmacovigilance aims to:

AEFI Monitoring in Africa 

AMP is collaborating with international and regional partners to monitor the safety of vaccines for various infectious diseases. Our primary work is a multi-year project in numerous African countries to establish AEFI (adverse events following immunization) monitoring in support of the Yellow Fever Initiative—led by WHO and UNICEF with the full engagement of ministries of health and financial support from Gavi, the Vaccine Alliance. 

We have also contributed to the development of vaccine adverse events surveillance for the introduction of the new meningococcal A conjugate vaccine in Burkina Faso. 

Since 2009 in sub-Saharan Africa, AMP has been involved in several projects related to pharmacovigilance studies in anticipation of the introduction of RTS, S/AS01E, the GlaxoSmithKline (GSK) candidate malaria vaccine.